相关实验视频
Updated: May 9, 2025
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
9.7K
抗糖尿病药物对男性不孕症的保护作用:来自孟德尔随机化的证据
Yuqi Li1,2, Tao Zhou1,2, Zhiyu Liu1,2
1Department of Urology, Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China.
Diabetology & metabolic syndrome
|April 28, 2025
概括
甲胺,SGLT2抑制剂,胰岛素和硫尿素可以通过向特定基因来降低男性不孕症 (MIF) 的风险. 这项研究强调了与糖尿病治疗相关的男性不孕症的潜在新疗法.
科学领域:
- 内分泌学和新陈代谢学
- 遗传学和基因组学 遗传学和基因组学
- 生殖医学 生殖医学
背景情况:
- 全球糖尿病患病率上升影响了年轻人群.
- 抗糖尿病药物越来越多地被用于非糖尿病疾病.
- 抗糖尿病药物对男性不孕症 (MIF) 的影响尚不清楚.
研究的目的:
- 调查抗糖尿病药物标与男性不孕症 (MIF) 风险之间的潜在因果关系.
- 澄清常用抗糖尿病药物对男性生殖健康的影响.
主要方法:
- 使用两个样本的门德尔随机化 (MR) 和基于摘要的MR (SMR) 分析.
- 使用与HbA1c和基因表达相关的遗传变异作为工具变量.
- 分析了2型糖尿病 (T2DM) 和血糖数据集的数据,包括对强度的敏感性分析.
主要成果:
- 确定了七种与五种抗糖尿病药物类别和MIF相关的重要药物标.
- 甲胺 (GPD1),SGLT2抑制剂 (SLC5A1),胰岛素类型 (IGF1R) 和硫尿素 (TRPM4,CPT1A) 显示MIF风险降低.
- SMR分析证实,针对CPE和TRPM的药物显著降低了MIF风险4.
结论:
- 甲福明,SGLT2抑制剂,胰岛素类型和硫氨酸尿素可能对男性不孕症 (MIF) 具有治疗潜力.
- 特定的基因 (GPD1,SLC5A1,IGF1R,TRPM4,CPT1A,CPE) 都与MIF的进展有关.
- 这些发现支持开发针对男性不孕症的个性化精密疗法.
相关概念视频
01:23Infertility in Males
153
Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...
153
01:43Sex-linked Disorders
98.0K
Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
98.0K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
133
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
133
01:22Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
01:41Spermatogenesis
101.7K
Spermatogenesis is the process by which haploid sperm cells are produced in the male testes. It starts with stem cells located close to the outer rim of seminiferous tubules. These spermatogonial stem cells divide asymmetrically to give rise to additional stem cells (meaning that these structures “self-renew”), as well as sperm progenitors, called spermatocytes. Importantly, this method of asymmetric mitotic division maintains a population of spermatogonial stem cells in the male...
101.7K
01:23Dipeptidyl Peptidase 4 Inhibitors
117
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
117